Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | A real-world study evaluating combined modality therapy for early-stage Hodgkin lymphoma

Karan Chohan • 28 Oct 2022
IWWM-11 2022
Hodgkin Lymphoma Lymphoma
RAPID

Karan Chohan, MD, Mayo Clinic, Rochester, MN, gives an overview of a real-world study which evaluated combined modality therapy in patients with Hodgkin lymphoma (HL), highlighting the improved progression-free survival (PFS) observed in these patients, and further comments on the value of real-world data in this setting. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Karan Chohan

0:56
Insurance-based disparities in patients with Waldenström’s macroglobulinemia
Karan Chohan • 28 Oct 2022
1:34
WM and the clinical implications of acquired von Willebrand syndrome
Karan Chohan • 28 Oct 2022
1:34
Genomic pathways differentiating IgM-MGUS from WM: the microRNA & gene expression landscape
Karan Chohan • 28 Oct 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals